ATE482696T1 - Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 - Google Patents

Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Info

Publication number
ATE482696T1
ATE482696T1 AT02784313T AT02784313T ATE482696T1 AT E482696 T1 ATE482696 T1 AT E482696T1 AT 02784313 T AT02784313 T AT 02784313T AT 02784313 T AT02784313 T AT 02784313T AT E482696 T1 ATE482696 T1 AT E482696T1
Authority
AT
Austria
Prior art keywords
cucuminoid
cyclooxygenase
expression
compositions
action
Prior art date
Application number
AT02784313T
Other languages
English (en)
Inventor
John Babish
Terrence Howell
Linda Pacioretty
Original Assignee
Metaproteomics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metaproteomics Llc filed Critical Metaproteomics Llc
Application granted granted Critical
Publication of ATE482696T1 publication Critical patent/ATE482696T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02784313T 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 ATE482696T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33506201P 2001-10-26 2001-10-26
PCT/US2002/034456 WO2003035007A2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
ATE482696T1 true ATE482696T1 (de) 2010-10-15

Family

ID=23310091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784313T ATE482696T1 (de) 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Country Status (14)

Country Link
US (1) US20030096027A1 (de)
EP (2) EP2253314A3 (de)
JP (3) JP2005506996A (de)
KR (1) KR20040054738A (de)
AT (1) ATE482696T1 (de)
AU (2) AU2002348096B2 (de)
CA (1) CA2464334C (de)
DE (1) DE60237836D1 (de)
DK (1) DK1446136T3 (de)
ES (1) ES2353868T3 (de)
MX (1) MXPA04003734A (de)
NZ (1) NZ532560A (de)
PT (1) PT1446136E (de)
WO (1) WO2003035007A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149113A1 (en) 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
EP2253314A3 (de) * 2001-10-26 2012-08-01 Metaproteomics, LLC Curcuminoidzusammensetzungen, die eine synergistische Hemmung der Expression und/oder Aktivität von Cyclooxygenase-2 aufweisen
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
US20060233902A1 (en) * 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
CA2483340A1 (en) * 2002-04-24 2003-11-06 Research Development Foundation Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
EP1523318A4 (de) * 2002-06-24 2007-07-04 Res Dev Foundation Behandlung des humanen multiplen myeloms durch curcumin
KR20050071605A (ko) * 2002-10-21 2005-07-07 메타프로테오믹스, 엘엘씨 염증반응과 관련된 병리학적 상태를 치료하거나 저해하는조성물
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
KR20060105429A (ko) * 2003-05-22 2006-10-11 메타프로테오믹스, 엘엘씨 염증을 약화시키기 위한 항염증성 약제학적 조성물 및 위의독성의 치료법 또는 예방법
ITMI20031098A1 (it) * 2003-05-30 2004-11-30 Indena Spa Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
EP1694335A4 (de) * 2003-08-26 2008-12-31 Res Dev Foundation Osteoklastogenese-hemmer und ihre verwendungen
JP2005154390A (ja) * 2003-11-28 2005-06-16 Morishita Jintan Kk 肝保護剤
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
AU2011202586B2 (en) * 2004-02-27 2012-03-22 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
JPWO2006043671A1 (ja) * 2004-10-22 2008-05-22 キリンホールディングス株式会社 転写因子Nrf2活性化剤およびその機能が付与された食品
EP2263663A1 (de) * 2004-11-13 2010-12-22 Metaproteomics, LLC Zusammensetzungen enthaltend Kurkuminoide und entweder alpha- oder beta-Säuren zur Behandlung von Diabetes
CA2618613A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
JP2009518439A (ja) * 2005-12-09 2009-05-07 メタプロテオミクス,エルエルシー ホップ及びアカシア産物によるプロテインキナーゼ調節
WO2007134868A2 (en) * 2006-05-24 2007-11-29 Dsm Ip Assets B.V. 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
WO2007149482A2 (en) * 2006-06-20 2007-12-27 Metaproteomics, Llc Xanthohumol based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
JP2010504332A (ja) * 2006-09-19 2010-02-12 ヒューマン バイオモレキュラル リサーチ インスティテュート アルツハイマー病の診断方法及び遺伝子マーカー
US8815306B2 (en) * 2007-03-19 2014-08-26 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
US8192768B2 (en) * 2007-04-03 2012-06-05 Laila Impex Synergistic anti-inflammatory and antioxidant dietary supplement compositions
AU2008251756B2 (en) * 2007-05-11 2013-06-06 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
CA2708613A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
NZ588927A (en) * 2008-04-02 2013-02-22 Metaproteomics Llc Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
AU2009234355A1 (en) * 2008-04-11 2009-10-15 Betal, Llc Xanthohumol compositions and methods for treating skin diseases or disorders
EP2799069A4 (de) * 2011-12-28 2015-12-23 Maruha Nichiro Corp Entgranulierungshemmer mit chlorophyll c
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び/又は認知機能を改善する組成物、及びこれを用いた医薬、食品
JP6242746B2 (ja) * 2014-05-26 2017-12-06 キリン株式会社 記憶学習機能を向上する医薬、食品、組成物
CN107582962A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种用于慢性萎缩性胃炎的配方及其提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149628A (ja) * 1993-11-30 1995-06-13 Suntory Ltd 脂質代謝改善剤
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JPH0873369A (ja) * 1994-09-01 1996-03-19 Fuairudo:Kk 健康茶
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
EP2253314A3 (de) * 2001-10-26 2012-08-01 Metaproteomics, LLC Curcuminoidzusammensetzungen, die eine synergistische Hemmung der Expression und/oder Aktivität von Cyclooxygenase-2 aufweisen
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Also Published As

Publication number Publication date
AU2008202916A1 (en) 2008-07-24
CA2464334C (en) 2012-01-10
DK1446136T3 (da) 2011-01-10
EP1446136A4 (de) 2007-01-10
WO2003035007A3 (en) 2003-09-18
EP1446136A2 (de) 2004-08-18
EP2253314A2 (de) 2010-11-24
PT1446136E (pt) 2010-12-29
NZ532560A (en) 2005-02-25
AU2002348096B2 (en) 2008-04-03
MXPA04003734A (es) 2005-06-20
WO2003035007A2 (en) 2003-05-01
AU2008202916B8 (en) 2010-06-10
AU2008202916B2 (en) 2010-06-03
ES2353868T3 (es) 2011-03-07
KR20040054738A (ko) 2004-06-25
EP1446136B1 (de) 2010-09-29
EP2253314A3 (de) 2012-08-01
JP2011068680A (ja) 2011-04-07
DE60237836D1 (de) 2010-11-11
JP2011093918A (ja) 2011-05-12
US20030096027A1 (en) 2003-05-22
JP2005506996A (ja) 2005-03-10
CA2464334A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ATE482696T1 (de) Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
PT1005271E (pt) Composicao biocida sinergica
EA200700382A1 (ru) Фунгицидные композиции
BR0312479A (pt) Composição de tratamento dos cabelos e/ou couro cabeludo, método de tratamento de caspa e uso de óleo de manjericão
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
DK1369039T3 (da) Synergistiske herbicide fremgangsmåder
ATE188341T1 (de) Konservierungsmittel und verfahren zur behandlung von holz
DE602004030535D1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
EA200600602A1 (ru) Синергические фунгицидные комбинации биологически активных веществ
ATE347401T1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
BRPI0307808A2 (pt) composição inibidora da lipase
DE60312004D1 (de) Zusammensetzungen enthaltend mindestens kürbisöl und borretschöl, deren verwendung als arzneimittel, dermatikum oder dermatokosmetische zusammensetzung
AR030487A1 (es) Una composicion herbicida sinergica de un compuesto de dehidrobenzotiofeno y un inhibidor del fotosistema ii y el metodo para el control sinergico de plantas no deseables con dicha composicion
ATE486567T1 (de) Orale zusammensetzung mit einer ersten zusammensetzung (a) und einer zweiten zusammensetzung (b) zur verwendung als gemische zur getrennten oder aufeinanderfolgenden verwendung in der kosmetischen behandlung des menschlichen körpers
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
SV1999000087A (es) Composiciones fungicidas para plantas de arroz-mejoradas y metodo para controlar plagas de las mismas
DE10394347T5 (de) Eine synergistische Zusammensetzung zur Behandlung von Hyperlipidämie
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
ATE152879T1 (de) Antiparasitäre zusammensetzung zur verwendung bei tieren
ATE400259T1 (de) Verwendung von colipase-lipase-hemmern bei der herstellung einer pharmazeutischen zusammensetzung zur prävention von adipositas
DE60216979D1 (de) Synergistische zusammensetzung aus trans-tetracos-15-ensäure und apocynin, und verwendung davon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1446136

Country of ref document: EP